U.S. Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, Infections) Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, and Others), and Rec

U.S. Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, Infections) Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, and Others), and Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, and Others), and By Place of Setting (Hospitals, Ambulatory Surgical Centers, and Office Based)

U.S. Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, Infections) Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, and Others), and Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, and Others), and By Place of Setting (Hospitals, Ambulatory Surgical Centers, and Office Based)

The soft connective tissue graft known as acellular dermal matrix (ADM) is created through a decellularization procedure that leaves the extracellular skin matrix intact. This structure acts as a scaffold for donor-side cells after implantation, which makes it easier for those cells to be incorporated and revascularized later on. Acellular dermal matrices (ADMs) are of major importance in managing full-thickness skin defects, both in acute and in chronic wounds. Based on the advantage of tissue specificity, ADMs provide the ideal scaffold for regenerative medicine and tissue engineering strategies to support the generation of vascularized tissue with dermal features. However, tissue source and processing methodologies which is used to produce ADMs, influences the biochemical and structural characteristics of the final scaffold and the resulting tissue and clinical outcome. Acellular dermal matrixes have been developed for the treatment of a range of conditions in which an intact dermal scapholding is required. Acellular dermal matrixes are typically freeze-dried on an intact basement membrane obtained from donor skin. The donor skin is typically either of human or porcine origin. The dermal matrix is treated to remove all immunogenic materials including sweat glands, fibroblasts, smooth muscle, and vascular endothelium.

Market Dynamics

Increasing research and development activities by the key market players is expected to drive the growth of the U.S. acellular dermal matrices market over the forecast period. For instance, on July 21, 2023, the University of Texas Health Science Center, a public research university at San Antonio, in Texas, U.S., initiated a clinical trial titled “Gingival Augmentation and Root Coverage Results with Superficial and Deep Cut Acellular Dermal Matrices”. The study is estimated to get completed by April 2026.

Key features of the study:

• This report provides an in-depth analysis of the U.S. acellular dermal matrices market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. acellular dermal matrices market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study includes Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, and AlloSource
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. acellular dermal matrices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. acellular dermal matrices market

Detailed Segmentation:

• By Origin:

Human Dermis

Porcine Dermis

Bovine Dermis

• By Application:

Acute Wounds

• Burns
• Trauma
• Cancers
• Infections

Chronic Wounds

• Diabetic Foot Ulcers
• Venous Leg Ulcers
• Pressure Ulcer
• Others

Reconstruction Procedures

• Abdominal Wall Procedures
• Breast Procedures
• Orthopedic Procedures
• Others
• By Place of Setting:

Hospitals

Ambulatory Surgical Centers

Office Based

• Company Profiles
• Integra LifeSciences Corporation
• AbbVie Inc.
• Johnson & Johnson
• HansBioMed
• Becton, Dickinson and Company
• Cook Group
• Smith & Nephew Plc.
• Reprise Biomedical
• Organogenesis Holdings Inc.
• Tissue Regenix
• LifeNet Health
• Zimmer Biomet Holdings, Inc.
• Stryker Corporation
• MiMedx Group
• PolyNovo Limited
• Fidia Pharma USA Inc.
• Baxter International Inc.
• In2Bones Global
• AlloSource